Elena Serban, Medical Oncologist at Bucharest Oncology Institute, shared a post on LinkedIn:
“Grateful to have attended the ESMO Advanced Course on ADC Development, Therapeutic Applications and Research in Gastrointestinal and Gynaecological Cancers.
Last week in Zurich, I had the opportunity to participate in one of the most insightful and forward-thinking educational programmes I’ve attended this year. The course offered a comprehensive deep-dive into antibody–drug conjugates (ADCs)—from their mechanisms of action and biological rationale to therapeutic applications across GI and gynaecological malignancies.
Over two intensive days, I was able to:
- Consolidate and update my knowledge on ADCs’ mechanisms of action
- Explore newly described toxicities, their management, and emerging safety patterns
- Understand mechanisms of resistance and how these guide next-generation ADC development
- Review complex clinical cases, real-world evidence, and evolving treatment sequences
- Discuss ongoing research, trial data, and the future landscape of targeted drug delivery
The scientific depth, clarity, and practical relevance were outstanding.
A special thank you to the ESMO faculty and organizers for creating such a high-quality learning environment, and to all the speakers for sharing their expertise, vision, and clinical experience. Your insights are invaluable and will directly impact how we refine patient care.
Grateful as always to ESMO for this opportunity to continue growing as an oncologist and for their commitment to advancing education in precision oncology.”
More posts featuring ESMO.